Review of rheumatoid arthritis disease outcome measures: Recommendations and its relevance in private practice

Publication date: Available online 23 July 2015 Source:Indian Journal of Rheumatology Author(s): Pravin Hissaria The ultimate goal of pharmacological treatment in Rheumatoid Arthritis (RA) is to reach and sustain remission, prevent functional disability and organ damage. Recent improvements and insights in RA treatment such as availability of wider range of disease modifying agents including biological agents have made ‘clinical remission’ a realistic target for many patients. To optimise RA treatment physicians must monitor the disease activity accurately to adjust treatment according to disease activity levels. In RA, several disease outcomes such as painful and swollen joints, functional impairment and acute phase reactants are recognized as manifestations of underlying disease process. To monitor the disease accurately, an index expressing these outcomes as a single continuous variable is required. The widely used disease outcome measures in clinical trials are the American College of Rheumatology (ACR) recommended indices: DAS28 (ESR or CRP), PAS, PAS-II, RAPID-3, SDAI and CDAI which have different relevance in clinical practice as compared to clinical trials. DAS28 hitherto considered gold standard in measuring RA outcomes in clinical trials may not hold appeal in clinical practice because of complexities associated with its calculations and waiting time due to inclusion of laboratory measurements. In recent times, simpler scores such as RAPID-3 and CDAI are b...
Source: Indian Journal of Rheumatology - Category: Rheumatology Source Type: research